[Correspondence] Feasibility of general population screening for type 1 diabetes in the UK: the ELSA study

Type 1 diabetes is a chronic autoimmune inflammatory disease resulting in loss of insulin-secreting β cells and the subsequent need for lifelong insulin therapy.1 Presymptomatic type 1 diabetes is marked by the presence of two or more islet autoantibodies. Detection at this early stage offers substantial benefits, including improved long-term glucose control, preparation time for insulin therapy, and a reduced risk of diabetic emergencies, such as diabetic ketoacidosis.2 Furthermore, the advent of disease-modifying therapies to delay the need for insulin makes it crucial to identify type 1 diabetes at the presymptomatic stage.